Thach-Giao Truong, MD
Medical director, Melanoma Program
Cleveland Clinic
Cleveland, OH
DISCUSSION QUESTIONS
- How do you balance efficacy, safety, patient preferences, goals of therapy, and quality-of-life when recommending a first-line regimen?
- How do you select a specific IO (immunotherapy) regimen?
- Do you face any barriers to use of a new IO option?
Thach-Giao Truong, MD: How much do you consider goals of therapy and quality of life? Have people come to you with concerns like that?
Mohammad Muhsin Chisti, MD: Obviously, our goal is remission of the disease. With immunotherapy, that has been achievable. You achieve a similar goal [when] selecting one of those doublet immunotherapy regimens.
Truong: I don’t know if you are familiar with the [SWOG Cancer Research Network] S1616 trial [NCT03033576], looking at…